The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis
Abstract
Psoriasis is characterized by activation of T cells with a type 1 cytokine profile. IL-12 and IL-23 produced by APCs are essential for inducing Th1 effector cells. Promising clinical results of administration of an Ab specific for the p40 subunit of IL-12 and IL-23 (anti-IL-12p40) have been reported recently. This study evaluated histological changes and mRNA expression of relevant cytokines and chemokines in psoriatic skin lesions following a single administration of anti-IL-12p40, using immunohistochemistry and real-time RT-PCR. Expression levels of type 1 cytokine (IFN-γ) and chemokines (IL-8, IFN-γ-inducible protein-10, and MCP-1) were significantly reduced at 2 wk posttreatment. The rapid decrease of these expression levels preceded clinical response and histologic changes. Interestingly, the level of an anti-inflammatory cytokine, IL-10, was also significantly reduced. Significant reductions in TNF-α levels and infiltrating T cells were observed in high responders (improvement in clinical score, ≥75% at 16 wk), but not in low responders. Of importance, the levels of APC cytokines, IL-12p40 and IL-23p19, were significantly decreased in both responder populations, with larger decreases in high responders. In addition, baseline levels of TNF-α significantly correlated with the clinical improvement at 16 wk, suggesting that these levels may predict therapeutic responsiveness to anti-IL-12p40. Thus, in a human Th1-mediated disease, blockade of APC cytokines by anti-IL-12p40 down-regulates expression of type 1 cytokines and chemokines that are downstream of IL-12/IL-23, and also IL-12/IL-23 themselves, with a pattern indicative of coordinated deactivation of APCs and Th1 cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Cited by
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.59 · Cited by 1,129
Tesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Self-citationMa, H.-L., Liang, S., Li, J., Napierata, L., Brown, T., Benoit, S., Senices, M., Gill, D., Dunussi-Joannopoulos, K., Collins, M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33263 · Cited by 544
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Moschen, A. R., Tilg, H., & Raine, T. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0084-8 · Cited by 473
Perera, G. K., Di Meglio, P., & Nestle, F. O. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132448 · Cited by 462
Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines
Fitch, E., Harper, E., Skorcheva, I., Kurtz, S. E., & Blauvelt, A. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0075-1 · Cited by 415
Angiogenesis drives psoriasis pathogenesis
Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00669.x · Cited by 383
The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Gee, K., Guzzo, C., Che Mat, N., Ma, W., & Kumar, A. (2009) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152809787582507 · Cited by 356
Guilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G., Bernard, F.-X., Lecron, J.-C., & Morel, F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902464 · Cited by 353
Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis
Guttman-Yassky, E., Lowes, M. A., Fuentes-Duculan, J., Zaba, L. C., Cardinale, I., Nograles, K. E., Khatcherian, A., Novitskaya, I., Carucci, J. A., Bergman, R., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7420 · Cited by 331
IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells
Goodman, W. A., Levine, A. D., Massari, J. V., Sugiyama, H., McCormick, T. S., & Cooper, K. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803721 · Cited by 329
Self-citationRes, P. C. M., Piskin, G., de Boer, O. J., van der Loos, C. M., Teeling, P., Bos, J. D., & Teunissen, M. B. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014108 · Cited by 328
Scanning the Immunopathogenesis of Psoriasis
Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., & Romanelli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010179 · Cited by 320
Zaba, L. C., Suárez-Fariñas, M., Fuentes-Duculan, J., Nograles, K. E., Guttman-Yassky, E., Cardinale, I., Lowes, M. A., & Krueger, J. G. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.046 · Cited by 303
Nedoszytko, B., Sokołowska-Wojdyło, M., Ruckemann-Dziurdzińska, K., Roszkiewicz, J., & Nowicki, R. J. (2014) · Advances in Dermatology and Allergology · doi:10.5114/pdia.2014.40920 · Cited by 292
From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited
Boniface, K., Blom, B., Liu, Y., & De Waal Malefyt, R. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00714.x · Cited by 218
“colleagues (125) further showed that the clinical improvement was associated with reduced expression of IL-12p40 and IL-23p19 but not of IL-12p35.”
BackgroundIL-17RC: a partner in IL-17 signaling and beyond
Ho, A. W., & Gaffen, S. L. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-009-0185-0 · Cited by 104
“Accordingly, clinical targeting of Th17 cells by antibodies that neutralize the IL-12/IL-23 p40 subunit results in a significant improvement in disease pathology in psoriatic patients, associated with a decrease in the mRNA of the p19 subunit of IL-23 [81, 82].”
Metadata
- Authors
- Toichi, E., Torres, G., McCormick, T. S., Chang, T., Mascelli, M. A., Kauffman, C. L., Aria, N., Gottlieb, A. B., Everitt, D. E., Frederick, B., Pendley, C. E., & Cooper, K. D.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10-01
- Volume
- 177
- Issue
- 7
- Pages
- 4917-4926
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1909667061
- Cited by
- 229
- References
- 2
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.